Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-29
2011-03-29
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
07915258
ABSTRACT:
The invention relates to compounds having the formula (I):Wherein R1, R2, R3and R4are as described herein. Also disclosed are the method of preparation and their use in therapy.
REFERENCES:
patent: 4345934 (1982-08-01), Fujimoto et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5808062 (1998-09-01), Domagala et al.
patent: 2009/0325968 (2009-12-01), Green et al.
patent: 2010/0210687 (2010-08-01), Cooper et al.
patent: 0576357 (1993-12-01), None
patent: 0656354 (1995-06-01), None
patent: WO 00/46209 (2000-08-01), None
patent: WO 2004/108728 (2004-12-01), None
patent: WO 2005/061504 (2005-07-01), None
Bouaboula, M., et. al., A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-Activated Protein Kinase Activation Stimulated by Insulin or Insulin-Like Growth Factor 1, The Journal of Biological Chemistry, vol. 272, No. 35, (1997), pp. 22330-22339.
Bouaboula, M., et. al., Stimulation of Cannabinoid Receptor CB1 Induces Krox-24 Expression in Human Astrocytoma Cells, The Journal of Biological Chemistry, vol. 270, No. 23, (1995), pp. 13973-13980.
Keshavamurthy, K. S., et. al., Preparation of Acid Anhydrides, Amides, and Esters Using Chlorosulfonyl Isocyanate as a Dehydrating Agent, Synthesis, (1982), pp. 506-508.
Mispelaere-Canivet, C., et. al., Pd2(dba)3/Xantphos-Catalyzed Cross-Coupling of Thiols and Aryl Bromides/Triflates, Tetrahedron, vol. 61, (2005), pp. 5253-5259.
Rinaldi-Carmona, M., et. al., Biochemical and Pharmacological Characterisation of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist, Life Sciences, vol. 56, No. 23/24, pp. 1941-1947, (1995).
Rinaldi-Carmona, M., et. al., Characterization of Two Cloned Human CB1 Cannabinoid Receptor Isoforms, The Journal of Pharmacology and Experimental Therapeutics, vol. 278, No. 2, pp. 871-878, (1996).
Rinaldi-Carmona, M., et. al., SR141716A, A Potent and Selective Antogonist of the Brain Cannabinoid Receptor, Febs Letters, vol. 350, (1994) pp. 240-244.
Rinaldi-Carmona, M., et. al., R147778 [5-(4-Bromophenyl)-1-(2,4-Dichlorophenyl)-4-ethyl-N-(1-Piperidinyl)-1H-Pyrazole-3-Carboxamide], A New Potent and Selective Antagonist of the CB1 Cannabinold Receptor: Biochemical and Pharmacological Characterization, The Journal of Pharmacology and Experimental Therapeutics, vol. 310, No. 3, (2004), pp. 905-914.
Qi, C.-M., et. al., Synthesis and Hybridizing Activity of Novel Chemical Hybridizing Agent Pyridazinone Derivatives, Youji Huaxue, (2004), vol. 24 No. 6, pp. 645-649 (Chinese Journal of Organic Chemistry, vol. 24, No. 6, (2004), pp. 645-649).
Broeck Didier Van
Congy Christian
Dos Santos Victor
Rinaldi-Carmona Murielle
Rouquette Arnaud
Farquharson, Esq. Serena
Jaisle Cecilia M
Sanofi-Aventis
Scully , Scott, Murphy & Presser, P.C.
Wilson James O
LandOfFree
Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702101